Literature DB >> 18204370

Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation.

Christopher J Scola1, Cuizhen Li, Katherine S Upchurch.   

Abstract

We reviewed the clinical manifestations of mesenteric vasculitis due to giant cell arteritis (GCA) and considered features of the mesenteric anatomy in relationship to disease expression. We compiled and reviewed a case series by systematic identification of patients previously reported in the English-language literature to have mesenteric involvement from known GCA. Included in the analysis was a detailed case review of a patient with GCA and small bowel infarction seen at our institution. Twelve patients were identified with mesenteric ischemia attributed to GCA. Concomitant cranial and abdominal symptoms were present in 7 of the 12 patients, and cranial symptoms were absent in 5 patients who presented with abdominal complaints. The abdominal symptoms fell within a spectrum ranging from chronic postprandial symptoms to acute abdominal pain. Survival was observed in only 6 of the 12 cases, 3 of whom required bowel resection and were treated with high-dose corticosteroids. Review of the anatomic features of the specialized splanchnic circulation reveals an extensive collateral network that may protect against early disease expression from ischemia, despite mesenteric arteritic involvement. Mesenteric vasculitis resulting in small bowel infarction has only rarely been described in GCA but represents a serious and potentially treatable complication. We propose an explanation, based on mesenteric vascular anatomy, for the infrequency of symptomatic expression of this entity and suggest that occult mesenteric GCA may be present far more often than recognized.

Entities:  

Mesh:

Year:  2008        PMID: 18204370     DOI: 10.1097/MD.0b013e3181646118

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  8 in total

1.  Gastric bleeding in giant cell arteritis.

Authors:  Austin Childress; Thomas J Kwarcinski; Joseph Scott H Bittle; Clayton Trimmer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-15

Review 2.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 3.  Gastrointestinal aspects of vasculitides.

Authors:  Medha Soowamber; Adam V Weizman; Christian Pagnoux
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-23       Impact factor: 46.802

Review 4.  Giant cell arteritis: ophthalmic manifestations of a systemic disease.

Authors:  Elisabeth De Smit; Eoin O'Sullivan; David A Mackey; Alex W Hewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-05       Impact factor: 3.117

Review 5.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

6.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

7.  Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study.

Authors:  Sergio Prieto-González; Ana García-Martínez; Itziar Tavera-Bahillo; José Hernández-Rodríguez; José Gutiérrez-Chacoff; Marco A Alba; Giuseppe Murgia; Georgina Espígol-Frigolé; Marcelo Sánchez; Pedro Arguis; Maria C Cid
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

8.  Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder.

Authors:  Muhammad Raza Cheema; Shakawan M Ismaeel
Journal:  Clin Interv Aging       Date:  2016-02-23       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.